Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice

Chi-Hao Wu, Hsin Yuan Chen, Chia-Woei Wang, Tzong Ming Shieh, Tsui-Chin Huang, Li Chun Lin, Kai Lee Wang, Shih-Min Hsia

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Endometrial cancer is the most common cancer in women, typically with onset after menopause. Isoliquiritigenin (ISL), a licorice flavonoid, was previously shown to have anti-oxidant, anti-inflammatory, and tumor suppression effects. In this study, we investigated the anti-tumor effect of ISL on human endometrial cancer both in vitro and in vivo. We used telomerase-immortalized human endometrial stromal cells (T-HESCs) and human endometrial cancer cell lines (Ishikawa, HEC-1A, and RL95-2 cells) as targets. The effects of ISL on cell proliferation, cell cycle regulation, and apoptosis or autophagy-related protein expression were examined. In addition, we conducted in vivo experiments to confirm the inhibitory effects of ISL on cancer cells. ISL significantly inhibited the viability of cancer cells in a dose- and timedependent manner but with little toxicity on normal cells. In addition, flow cytometry analysis indicated that ISL induced sub-G1 or G2/M phase arrest. ISL treatment activated the extracellular signal regulated kinase signaling pathway to enhance the protein expression of caspase-7/LC3BII associated with apoptosis/autophagy. Furthermore, ISL suppressed xenograft tumor growth in vivo. Taken together, these findings suggest that ISL may induce apoptosis, autophagy, and cell growth inhibition, indicating its potential as a therapeutic agent for human endometrial cancer.

Original languageEnglish
Pages (from-to)73432-73447
Number of pages16
JournalOncotarget
Volume7
Issue number45
DOIs
Publication statusPublished - 2016

Fingerprint

Autophagy
Endometrial Neoplasms
Apoptosis
Growth
Neoplasms
Glycyrrhiza
Caspase 7
isoliquiritigenin
G2 Phase
Telomerase
Extracellular Signal-Regulated MAP Kinases
Stromal Cells
Menopause
Flavonoids
Heterografts
Oxidants
Cell Division
Cell Survival
Cell Cycle
Flow Cytometry

Keywords

  • Apoptosis
  • Autophagy
  • Endometrial cancer
  • Isoliquiritigenin

ASJC Scopus subject areas

  • Oncology

Cite this

Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. / Wu, Chi-Hao; Chen, Hsin Yuan; Wang, Chia-Woei; Shieh, Tzong Ming; Huang, Tsui-Chin; Lin, Li Chun; Wang, Kai Lee; Hsia, Shih-Min.

In: Oncotarget, Vol. 7, No. 45, 2016, p. 73432-73447.

Research output: Contribution to journalArticle

Wu, Chi-Hao ; Chen, Hsin Yuan ; Wang, Chia-Woei ; Shieh, Tzong Ming ; Huang, Tsui-Chin ; Lin, Li Chun ; Wang, Kai Lee ; Hsia, Shih-Min. / Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. In: Oncotarget. 2016 ; Vol. 7, No. 45. pp. 73432-73447.
@article{4c411b199993417c8064a0434cc7689e,
title = "Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice",
abstract = "Endometrial cancer is the most common cancer in women, typically with onset after menopause. Isoliquiritigenin (ISL), a licorice flavonoid, was previously shown to have anti-oxidant, anti-inflammatory, and tumor suppression effects. In this study, we investigated the anti-tumor effect of ISL on human endometrial cancer both in vitro and in vivo. We used telomerase-immortalized human endometrial stromal cells (T-HESCs) and human endometrial cancer cell lines (Ishikawa, HEC-1A, and RL95-2 cells) as targets. The effects of ISL on cell proliferation, cell cycle regulation, and apoptosis or autophagy-related protein expression were examined. In addition, we conducted in vivo experiments to confirm the inhibitory effects of ISL on cancer cells. ISL significantly inhibited the viability of cancer cells in a dose- and timedependent manner but with little toxicity on normal cells. In addition, flow cytometry analysis indicated that ISL induced sub-G1 or G2/M phase arrest. ISL treatment activated the extracellular signal regulated kinase signaling pathway to enhance the protein expression of caspase-7/LC3BII associated with apoptosis/autophagy. Furthermore, ISL suppressed xenograft tumor growth in vivo. Taken together, these findings suggest that ISL may induce apoptosis, autophagy, and cell growth inhibition, indicating its potential as a therapeutic agent for human endometrial cancer.",
keywords = "Apoptosis, Autophagy, Endometrial cancer, Isoliquiritigenin",
author = "Chi-Hao Wu and Chen, {Hsin Yuan} and Chia-Woei Wang and Shieh, {Tzong Ming} and Tsui-Chin Huang and Lin, {Li Chun} and Wang, {Kai Lee} and Shih-Min Hsia",
year = "2016",
doi = "10.18632/oncotarget.12369",
language = "English",
volume = "7",
pages = "73432--73447",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "45",

}

TY - JOUR

T1 - Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice

AU - Wu, Chi-Hao

AU - Chen, Hsin Yuan

AU - Wang, Chia-Woei

AU - Shieh, Tzong Ming

AU - Huang, Tsui-Chin

AU - Lin, Li Chun

AU - Wang, Kai Lee

AU - Hsia, Shih-Min

PY - 2016

Y1 - 2016

N2 - Endometrial cancer is the most common cancer in women, typically with onset after menopause. Isoliquiritigenin (ISL), a licorice flavonoid, was previously shown to have anti-oxidant, anti-inflammatory, and tumor suppression effects. In this study, we investigated the anti-tumor effect of ISL on human endometrial cancer both in vitro and in vivo. We used telomerase-immortalized human endometrial stromal cells (T-HESCs) and human endometrial cancer cell lines (Ishikawa, HEC-1A, and RL95-2 cells) as targets. The effects of ISL on cell proliferation, cell cycle regulation, and apoptosis or autophagy-related protein expression were examined. In addition, we conducted in vivo experiments to confirm the inhibitory effects of ISL on cancer cells. ISL significantly inhibited the viability of cancer cells in a dose- and timedependent manner but with little toxicity on normal cells. In addition, flow cytometry analysis indicated that ISL induced sub-G1 or G2/M phase arrest. ISL treatment activated the extracellular signal regulated kinase signaling pathway to enhance the protein expression of caspase-7/LC3BII associated with apoptosis/autophagy. Furthermore, ISL suppressed xenograft tumor growth in vivo. Taken together, these findings suggest that ISL may induce apoptosis, autophagy, and cell growth inhibition, indicating its potential as a therapeutic agent for human endometrial cancer.

AB - Endometrial cancer is the most common cancer in women, typically with onset after menopause. Isoliquiritigenin (ISL), a licorice flavonoid, was previously shown to have anti-oxidant, anti-inflammatory, and tumor suppression effects. In this study, we investigated the anti-tumor effect of ISL on human endometrial cancer both in vitro and in vivo. We used telomerase-immortalized human endometrial stromal cells (T-HESCs) and human endometrial cancer cell lines (Ishikawa, HEC-1A, and RL95-2 cells) as targets. The effects of ISL on cell proliferation, cell cycle regulation, and apoptosis or autophagy-related protein expression were examined. In addition, we conducted in vivo experiments to confirm the inhibitory effects of ISL on cancer cells. ISL significantly inhibited the viability of cancer cells in a dose- and timedependent manner but with little toxicity on normal cells. In addition, flow cytometry analysis indicated that ISL induced sub-G1 or G2/M phase arrest. ISL treatment activated the extracellular signal regulated kinase signaling pathway to enhance the protein expression of caspase-7/LC3BII associated with apoptosis/autophagy. Furthermore, ISL suppressed xenograft tumor growth in vivo. Taken together, these findings suggest that ISL may induce apoptosis, autophagy, and cell growth inhibition, indicating its potential as a therapeutic agent for human endometrial cancer.

KW - Apoptosis

KW - Autophagy

KW - Endometrial cancer

KW - Isoliquiritigenin

UR - http://www.scopus.com/inward/record.url?scp=84995741440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995741440&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12369

DO - 10.18632/oncotarget.12369

M3 - Article

C2 - 27708238

AN - SCOPUS:84995741440

VL - 7

SP - 73432

EP - 73447

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -